QQQ   305.36 (+0.58%)
AAPL   153.37 (+1.08%)
MSFT   264.22 (+2.90%)
META   190.42 (+2.34%)
GOOGL   105.17 (+2.21%)
AMZN   99.69 (-2.44%)
TSLA   195.04 (+0.14%)
NVDA   216.56 (+2.69%)
NIO   10.73 (-1.83%)
BABA   104.32 (-1.07%)
AMD   83.74 (+0.07%)
T   19.36 (-1.12%)
F   13.20 (+0.46%)
MU   60.52 (+0.90%)
CGC   2.78 (-5.76%)
GE   81.11 (-1.51%)
DIS   109.73 (-0.13%)
AMC   6.24 (-8.24%)
PFE   43.47 (-0.66%)
PYPL   81.87 (-0.56%)
NFLX   358.42 (-0.85%)
QQQ   305.36 (+0.58%)
AAPL   153.37 (+1.08%)
MSFT   264.22 (+2.90%)
META   190.42 (+2.34%)
GOOGL   105.17 (+2.21%)
AMZN   99.69 (-2.44%)
TSLA   195.04 (+0.14%)
NVDA   216.56 (+2.69%)
NIO   10.73 (-1.83%)
BABA   104.32 (-1.07%)
AMD   83.74 (+0.07%)
T   19.36 (-1.12%)
F   13.20 (+0.46%)
MU   60.52 (+0.90%)
CGC   2.78 (-5.76%)
GE   81.11 (-1.51%)
DIS   109.73 (-0.13%)
AMC   6.24 (-8.24%)
PFE   43.47 (-0.66%)
PYPL   81.87 (-0.56%)
NFLX   358.42 (-0.85%)
QQQ   305.36 (+0.58%)
AAPL   153.37 (+1.08%)
MSFT   264.22 (+2.90%)
META   190.42 (+2.34%)
GOOGL   105.17 (+2.21%)
AMZN   99.69 (-2.44%)
TSLA   195.04 (+0.14%)
NVDA   216.56 (+2.69%)
NIO   10.73 (-1.83%)
BABA   104.32 (-1.07%)
AMD   83.74 (+0.07%)
T   19.36 (-1.12%)
F   13.20 (+0.46%)
MU   60.52 (+0.90%)
CGC   2.78 (-5.76%)
GE   81.11 (-1.51%)
DIS   109.73 (-0.13%)
AMC   6.24 (-8.24%)
PFE   43.47 (-0.66%)
PYPL   81.87 (-0.56%)
NFLX   358.42 (-0.85%)
QQQ   305.36 (+0.58%)
AAPL   153.37 (+1.08%)
MSFT   264.22 (+2.90%)
META   190.42 (+2.34%)
GOOGL   105.17 (+2.21%)
AMZN   99.69 (-2.44%)
TSLA   195.04 (+0.14%)
NVDA   216.56 (+2.69%)
NIO   10.73 (-1.83%)
BABA   104.32 (-1.07%)
AMD   83.74 (+0.07%)
T   19.36 (-1.12%)
F   13.20 (+0.46%)
MU   60.52 (+0.90%)
CGC   2.78 (-5.76%)
GE   81.11 (-1.51%)
DIS   109.73 (-0.13%)
AMC   6.24 (-8.24%)
PFE   43.47 (-0.66%)
PYPL   81.87 (-0.56%)
NFLX   358.42 (-0.85%)
NASDAQ:LPCN

Lipocine - LPCN Stock Forecast, Price & News

$0.55
+0.01 (+1.98%)
(As of 02/7/2023 11:59 AM ET)
Add
Compare
Today's Range
$0.53
$0.56
50-Day Range
$0.39
$0.58
52-Week Range
$0.36
$1.89
Volume
22,838 shs
Average Volume
117,614 shs
Market Capitalization
$48.68 million
P/E Ratio
13.75
Dividend Yield
N/A
Price Target
$4.00

Lipocine MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
627.3% Upside
$4.00 Price Target
Short Interest
Bearish
1.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$10,217 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.13) to ($0.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

832nd out of 1,027 stocks

Pharmaceutical Preparations Industry

407th out of 500 stocks

LPCN stock logo

About Lipocine (NASDAQ:LPCN) Stock

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The firm is involved in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Stock News Headlines

Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
Lipocine to Present at Biotech Showcase
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
LPCN: TLANDO Launched
Lipocine: Q2 Earnings Snapshot
Recap: Lipocine Q2 Earnings - Benzinga
Form 8-K Lipocine Inc. For: Aug 08 - StreetInsider.com
See More Headlines
Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings
11/09/2022
Today
2/07/2023
Next Earnings (Estimated)
3/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPCN
Employees
13
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+627.3%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-630,000.00
Pretax Margin
24.69%

Debt

Sales & Book Value

Annual Sales
$16.14 million
Cash Flow
$0.04 per share
Book Value
$0.52 per share

Miscellaneous

Free Float
83,908,000
Market Cap
$48.68 million
Optionable
Optionable
Beta
0.88

Social Links


Key Executives

  • Mahesh V. PatelMahesh V. Patel
    President, Chief Executive & Financial Officer
  • George G Nomikos
    Chief Medical Officer
  • Anthony DelConte
    Chief Medical Director
  • Nachiappan Chidambaram
    Vice President-Product Development
  • Krista Fogarty
    Chief Accounting Officer













LPCN Stock - Frequently Asked Questions

What is Lipocine's stock price forecast for 2023?

0 Wall Street analysts have issued 1 year target prices for Lipocine's stock. Their LPCN share price forecasts range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 641.7% from the stock's current price.
View analysts price targets for LPCN
or view top-rated stocks among Wall Street analysts.

How have LPCN shares performed in 2023?

Lipocine's stock was trading at $0.3978 at the start of the year. Since then, LPCN shares have increased by 35.6% and is now trading at $0.5393.
View the best growth stocks for 2023 here
.

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our LPCN earnings forecast
.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) released its quarterly earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03).

What other stocks do shareholders of Lipocine own?
What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Who are Lipocine's major shareholders?

Lipocine's stock is owned by a number of retail and institutional investors. Top institutional investors include Wealth Effects LLC (1.33%), Bailard Inc. (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include John W Higuchi, Krista Fogarty, Mahesh V Patel, Morgan R Brown and Spyros Papapetropoulos.
View institutional ownership trends
.

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $0.54.

How much money does Lipocine make?

Lipocine (NASDAQ:LPCN) has a market capitalization of $47.73 million and generates $16.14 million in revenue each year. The specialty pharmaceutical company earns $-630,000.00 in net income (profit) each year or $0.04 on an earnings per share basis.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 2/7/2023 by MarketBeat.com Staff